Abstract #2314

Weekly T2’ and rOEF-mapping monitoring tumor oxygenation in patients with recurrent glioblastoma undergoing antiangiogenetic therapy

Katharina J. Wenger¹, Elke Hattingen¹, Joachim P. Steinbach², Oliver Bähr², Marlies Wagner¹, Ralf Deichmann³, and Jan-Rüdiger Schüre¹

¹Institute of Neuroradiology, University Hospital Frankfurt, Frankfurt am Main, Germany, ²Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Frankfurt am Main, Germany, ³Brain Imaging Center, University Hospital Frankfurt, Frankfurt am Main, Germany

For tumor treatment with bevacizumab (BEV), a VEGF-specific antibody, some preclinical reports describe a partial normalization of vessels resulting in a transient improvement in tumor oxygenation, while others observed a decrease in neovascularization, with induction of intratumoral hypoxia. By weekly monitoring rOEF with MRI in six glioblastoma patients until tumor progression according to RANO, we were able to discriminate between two tumor phenotypes with different biological behavior.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.